Tag: rivaroxaban
1. Therapeutic anticoagulation with rivaroxaban or enoxaparin did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation.
2. Net clinical benefit composite of death, thrombotic events, and major or clinically relevant non-major bleeding was not significantly different between groups.
Evidence Rating Level: 1 (Excellent)
Study Rundown: COVID-19 is associated with...
1. Patients who received rivaroxaban had a statistically significantly longer mean time until occurrence of a major clinical event compared to those who received warfarin.
2. The incidence of secondary-outcome events such as transient ischemic attack (TIA), valve thrombosis, and non-CNS embolism were similar between groups.
Evidence Rating Level: 1 (Excellent)
Study...
1. Patients who received rivaroxaban had a statistically significantly longer mean time until occurrence of a major clinical event compared to those who received warfarin.
2. The incidence of secondary-outcome events such as transient ischemic attack (TIA), valve thrombosis, and non-CNS embolism were similar between groups.
Evidence Rating Level: 1 (Excellent)
Study...
1. Microbleeds increase risk of intracerebral hemorrhage, ischemic stroke, recurrent stroke, and mortality.
2. Microbleeds do not appear to influence the effects of rivaroxaban treatment.
Evidence Rating Level: 2 (Good)
Cerebral microbleeds are known to be associated with intracerebral hemorrhage and recurrent. Questions have been raised related to antithrombitic treatment for those...
1. In this observational study, patients who received one of three direct oral anticoagulants (DOACs) were significantly less likely to have an osteoporotic hip or vertebral fracture compared to those who received warfarin.
2. No difference in fracture risk was detected between individual DOACs.
Evidence Rating Level: 2 (Good)
Study Rundown: Osteoporotic...
1. After successful transcatheter aortic valve replacement, compared to an anti-platelet based strategy, patients that received an anti-coagulation strategy including rivaroxaban at a dose of 10 mg daily had a higher risk of death, thromboembolic complications, and bleeding.
Evidence Rating: 1 (Excellent)
Transcatheter aortic-valve replacement (TAVR) is a treatment option for patients...
1. After successful transcatheter aortic valve replacement, compared to an anti-platelet based strategy, patients that received an anti-coagulation strategy including rivaroxaban at a dose of 10 mg daily had a higher risk of death, thromboembolic complications, and bleeding.
Evidence Rating: 1 (Excellent)
Transcatheter aortic-valve replacement (TAVR) is a treatment option for patients...
The association of depression with subsequent dementia diagnosis: A Swedish nationwide cohort study from 1964 to 2016
1. There is a significantly increased risk of dementia in patients with previously diagnosed depression, with the highest risk observed in patients diagnosed with severe depression
Evidence Level: 2 (Good)
The prevalence of dementia is on...
1. In this randomized study comparing the efficacy of rivaroxaban with warfarin, dose-adjusted rivaroxaban treatment resulted in near doubling of risk for recurrent thrombosis.
2. The two treatment groups experienced similar bleeding outcomes, but patients in the rivaroxaban group had a higher stroke incidence rate.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Antiphospholipid...